Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $3.2 million.

  • Cyclerion Therapeutics' Shares Outstanding (Weighted Average) rose 2767.22% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 2767.22%. This contributed to the annual value of $2.5 million for FY2024, which is 769.89% up from last year.
  • According to the latest figures from Q3 2025, Cyclerion Therapeutics' Shares Outstanding (Weighted Average) is $3.2 million, which was up 2767.22% from $3.1 million recorded in Q2 2025.
  • Cyclerion Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $43.3 million for Q3 2021, and its period low was $43425.0 during Q1 2022.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $2.5 million (2024), whereas its average is $9.8 million.
  • Per our database at Business Quant, Cyclerion Therapeutics' Shares Outstanding (Weighted Average) tumbled by 9987.26% in 2022 and then soared by 491093.84% in 2023.
  • Over the past 5 years, Cyclerion Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $39.1 million in 2021, then plummeted by 94.45% to $2.2 million in 2022, then rose by 7.59% to $2.3 million in 2023, then rose by 7.7% to $2.5 million in 2024, then rose by 28.08% to $3.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $3.2 million in Q3 2025, compared to $3.1 million in Q2 2025 and $2.6 million in Q1 2025.